| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919803 | Radiotherapy and Oncology | 2011 | 7 Pages |
Abstract
We conclude that the XRCC1 Arg280His polymorphism may be protective against the development of high-grade late toxicity after radiotherapy in prostate cancer patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Tanja Langsenlehner, Wilfried Renner, Armin Gerger, Günter Hofmann, Eva-Maria Thurner, Karin S. Kapp, Uwe Langsenlehner,